GT Biopharma, Inc.GTBPNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-10.4%
5Y CAGR+7.3%
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-10.4%/yr
vs -0.1%/yr prior
5Y CAGR
+7.3%/yr
Recent deceleration
Acceleration
-10.3pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$8.95M+4.5%
2024$8.57M+20.5%
2023$7.11M-42.9%
2022$12.45M-74.0%
2021$47.92M+663.2%
2020$6.28M-35.8%
2019$9.79M-21.6%
2018$12.49M-90.7%
2017$134.50M+1501.4%
2016$8.40M-